Nådde inte primärt mål Efter utgången av kvartalet rapporterade Stayble top-line data från bolagets ...
AcouSort genomför mellan 16 november till den 30 november år 2023 en företrädesemission.
Utifrån nuvarande estimat samt tillämpade värderingsantaganden i denna analysuppdatering upprepar vi...
Redeye updates its view of Curasight following the Q3 report and recent events in the company.
We hosted CEO at our Investor Days Seminar 23/11 Promising commentary around finalised Thebalux acqu...
Redeye saw sales and results that were below our expectations.
Försäljningen under press under kvartalet men det ser ljusare ut framöver Omsättningen sjönk 16% y/...
B2B fortsätter att leverera Omsättningen i kvartalet uppgick till 48,3 mkr vilket motsvarar en ökni...
Redeye believes, in terms of cost restructuring, that the worst will soon be over for Northbaze Grou...
Redeye updates its view on Beyond Frames after the Q3’2023 report.
Atria hosted its CMD event yesterday. The event did not offer any large surprises as strategy and fi...
Redeye comments on Lipigon's Q3 report 2023. The main event since our last comment is the applicatio...
Redeye returns with a slightly upwards adjusted valuation following the XS003 data and capital marke...
STENOCARE announced on November 23rd that the company has signed agreements that will make a new pro...
CirChem har publicerat bolagets delårsrapport för det tredje kvartalet 2023.
Under det tredje kvartalet år 2023 fortsatte Windon Energy Group AB (”Windon” eller ”Bolaget”) uppvi...
Redeye comments on Mestro’s Q3 2023 report, which was stable but showed weakness on the CARR and sal...
Improved gross margin but weak revenue.
Redeye comments on Coala Life’s Q3’23 report, noting that the reported figures are in line with the ...
Redeye comments on Fragbite Groups Q3’23 report, showing stronger sales than expected and profitabil...